A recent study by researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center shows cognitive computing can help doctors find more clinical trials and therapeutic options for their cancer patients based on the genetic makeup of their tumors.
Scientists from the University of North Carolina (UNC) and North Carolina State University have developed a melanin-enhanced cancer immunotherapy treatment that boosts a naturally occurring immune response against skin cancer cells in mice.
Pharmaceutical company Astellas Pharma has been named a Best Place to Work for lesbian, gay, bisexual and transgender equality as it obtained a perfect score on the Human Rights Campaign Foundation’s (HRC) Corporate Equality Index (CEI).
Abbott has received approval from Japan’s Ministry of Health, Labor and Welfare for the company’s MitraClip, making it the first minimally invasive device to treat people in Japan with mitral regurgitation (MR) heart disease.
Novartis recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for what it calls a novel immunocellular therapy and one-time treatment that utilizes a patient’s own T cells to fight cancer.
More than 200 patient groups have sent a letter to congressional leaders urging them to not end the Orphan Drug Tax Credit as part of the recent tax bill proposals, which they claim would result in one-third fewer treatments for rare diseases.
Scientists from New York-Presbyterian Hospital and Weill Cornell Medicine are calling for deeper clinical trials for newer, nonchemotherapy drugs that they say will benefit patients with mantle cell lymphoma (MCL), a blood cancer.
The U.S. Food and Drug Administration (FDA) recently granted fast track designation to Astellas Pharma to develop gilteritinib, an investigational compound, for patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML).
Astellas Pharma, and Seattle Genetics recently began dosing the first patient in a registrational, phase two clinical trial of enfortumab vedotin for patients with certain forms of urothelial bladder cancer.
Apricus Biosciences said in a release that its CEO, Richard Pascoe, recently addressed the 2017 BIO Investor Forum in San Francisco, where he updated attendees on the company’s Vitaros, an erectile dysfunction treatment under development in the U.S.
The American Hospital Association (AHA) is speaking out against the recent executive order regarding health care signed by President Donald Trump, warning of the repercussions the order would have on the millions of Americans who are managing chronic and other pre-existing conditions.
The U.S. Food and Drug Administration agreed to review Amgen’s supplemental biologics license application for Prolia (denosumab), a drug targeting patients with glucocorticoid-induced osteoporosis (GIOP), an Amgen release said.
Medical University of South Carolina (MUSC) transplant doctors are putting up a red flag about the proposed changes to the liver allocation system made by the United Network for Organ Sharing (UNOS) recently, saying the changes would result in fewer donated livers for the state.